Generated record quarterly net revenues of $148.3 million, representing year-over-year growth of 12.5%, and record Purified Cortrophin® Gel net ...
Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE) ...
Journey Medical Corporation (Nasdaq: DERM) ("Journey Medical” or "the Company”, "we”, or "our”), a commercial-stage ...
Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...
Q3 2024 Earnings Call Transcript November 11, 2024 Operator: Thank you for standing by. My name is John, and I’ll be your ...
These risks are described in the cautionary note regarding forward-looking statements, risk factors and management’s discussion and analysis of financial condition and results of operations sections ...
Third Quarter Total Net Product Sales of $28.7 MillionRolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 ...
Tier Institutional Healthcare Investors -- -- Advancement of IkT-001Pro into a Late-Stage Clinical Trial Program in Pulmonary ...
Third quarter results included the following highlights (our discussion below focuses on a comparison of third quarter 2024 to second quarter 2024 given the acquisition of Spectrum and the generic ...
Received tentative approval from the FDA for YUTREPIATM (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) ...
ReShape Lifesciences Inc. ( NASDAQ: RSLS) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Michael Miller - Rx Communications Paul Hickey - President and CEO Thomas Stankovich - CFO ...
Ovintiv reports in U.S. dollars unless otherwise noted. Production, sales and reserves estimates are reported on an ...